Joseph Thome
Stock Analyst at TD Cowen
(4.90)
# 257
Out of 4,512 analysts
397
Total ratings
59.3%
Success rate
26.1%
Average return
Main Sectors:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Reiterated: Buy | $50 → $57 | $50.97 | +11.83% | 20 | Jul 13, 2026 | |
| ANAB AnaptysBio | Maintained: Buy | $75 | $67.13 | +11.73% | 24 | Jul 13, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintained: Buy | n/a | $72.65 | - | 7 | Jun 30, 2026 | |
| DYN Dyne Therapeutics | Initiated Coverage: Buy | n/a | $23.75 | - | 1 | Jun 26, 2026 | |
| QURE uniQure | Maintained: Buy | n/a | $42.23 | - | 26 | Jun 17, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $275 → $300 | $232.26 | +29.17% | 34 | Jun 17, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $13.16 | - | 21 | Jun 14, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $275 | $237.35 | +15.86% | 28 | Jun 12, 2026 | |
| NGEN NervGen Pharma | Initiated Coverage: Buy | n/a | $1.91 | - | 1 | Jun 11, 2026 | |
| UTHR United Therapeutics | Maintained: Buy | $675 | $525.82 | +28.37% | 29 | Jun 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $75.49 | - | 8 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $36.35 | - | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.34 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $90 | $79.70 | +12.92% | 46 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $22.47 | - | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $66.98 | - | 16 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $125 → $145 | $120.04 | +20.79% | 8 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.55 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.47 | - | 10 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $40.45 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.03 | - | 16 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $18.11 | - | 6 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $5.13 | +153.41% | 21 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.10 | - | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.99 | n/a | 9 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 5 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 | $124.12 | n/a | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $13.83 | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $145.90 | n/a | 1 | Oct 1, 2020 |
Alkermes
Jul 13, 2026
Reiterated: Buy
Price Target: $50 → $57
Current: $50.97
Upside: +11.83%
AnaptysBio
Jul 13, 2026
Maintained: Buy
Price Target: $75
Current: $67.13
Upside: +11.73%
Arrowhead Pharmaceuticals
Jun 30, 2026
Maintained: Buy
Price Target: n/a
Current: $72.65
Upside: -
Dyne Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $23.75
Upside: -
uniQure
Jun 17, 2026
Maintained: Buy
Price Target: n/a
Current: $42.23
Upside: -
Axsome Therapeutics
Jun 17, 2026
Maintained: Buy
Price Target: $275 → $300
Current: $232.26
Upside: +29.17%
Intellia Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: n/a
Current: $13.16
Upside: -
Jazz Pharmaceuticals
Jun 12, 2026
Maintained: Buy
Price Target: $275
Current: $237.35
Upside: +15.86%
NervGen Pharma
Jun 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $1.91
Upside: -
United Therapeutics
Jun 5, 2026
Maintained: Buy
Price Target: $675
Current: $525.82
Upside: +28.37%
May 20, 2026
Maintained: Buy
Price Target: n/a
Current: $75.49
Upside: -
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $36.35
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $1.34
Upside: -
May 8, 2026
Upgraded: Buy
Price Target: $75 → $90
Current: $79.70
Upside: +12.92%
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $22.47
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $66.98
Upside: -
May 7, 2026
Rated: Buy
Price Target: $125 → $145
Current: $120.04
Upside: +20.79%
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $6.55
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $3.47
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $40.45
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $19.03
Upside: -
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $18.11
Upside: -
Apr 30, 2026
Maintained: Buy
Price Target: $13
Current: $5.13
Upside: +153.41%
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $5.10
Upside: -
Jul 19, 2024
Rated: Hold
Price Target: n/a
Current: $20.99
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
May 24, 2023
Maintained: Hold
Price Target: $40
Current: $124.12
Upside: n/a
Oct 10, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $13.83
Upside: n/a
Oct 1, 2020
Reiterated: Buy
Price Target: n/a
Current: $145.90
Upside: n/a